Brief Communication abstract
Nature Neuroscience 10, 411 - 413 (2007)
Published online: 25 February 2007 | doi:10.1038/nn1860
Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome
Fabian Fernandez1, Wade Morishita1, Elizabeth Zuniga1, James Nguyen1, Martina Blank1, Robert C Malenka1 & Craig C Garner1
Ts65Dn mice, a model for Down syndrome, have excessive inhibition in the dentate gyrus, a condition that could compromise synaptic plasticity and mnemonic processing. We show that chronic systemic treatment of these mice with GABAA antagonists at non-epileptic doses causes a persistent post-drug recovery of cognition and long-term potentiation. These results suggest that over-inhibition contributes to intellectual disabilities associated with Down syndrome and that GABAA antagonists may be useful therapeutic agents for this disorder.
- Department of Psychiatry and Behavioral Sciences, Nancy Pritzker Laboratory, Stanford University, Palo Alto, California 94304-5485, USA.
Correspondence to: Craig C Garner1 e-mail: cgarner@stanford.edu
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Gender and Strain Influence on Neurogenesis in Dentate Gyrus of Young RatsJournal of Cerebral Blood Flow & Metabolism Original Article
Treatment of opioid-induced constipation with oral naloxone: A pilot studyClinical Pharmacology and Therapeutics Original Article
Arrested maturation of excitatory synapses in autosomal dominant lateral temporal lobe epilepsyNature Medicine Article (01 Oct 2009)
An L-type calcium-channel gene mutated in incomplete X-linked congenital stationary night blindnessNature Genetics Letter (01 Jul 1998)
High-throughput screening of novel antagonists on melanin-concentrating hormone receptor-1Acta Pharmacologica Sinica Original Article
See all 7 matches for Research
